

Pending Claims

Listing of claims:

1. (previously presented) A method for the treatment or prophylaxis of a human infected with hepatitis B virus comprising administering in combination or alternation an effective amount of:
 β-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (β-L-FTC);
 1-(2'-deoxy-2'-fluoro-β-L-arabinofuranosyl)-thymine (L-FMAU); and
 interferon;
or their pharmaceutically acceptable salts, independently optionally in pharmaceutically acceptable carriers.
2. (original) The method of claim 1, wherein the β-L-FTC is in substantially pure form.
3. (original) The method of claim 1, wherein the β-L-FTC is at least 90% by weight of the β-L-isomer.
4. (original) The method of claim 1, wherein the β-L-FTC is at least 95% by weight of the β-L-isomer.
5. (previously presented) The method of claim 1, wherein the interferon is selected from the group consisting of interferon alpha, pegylated interferon alpha, interferon alpha-2a, interferon alpha-2b, pegylated interferon alpha-2a, pegylated interferon alpha-2b, interferon beta, interferon gamma, interferon tau, interferon omega, consensus interferon, interferon alphacon-1, natural interferon, interferon beta-la, oral interferon alpha, interferon gamma-lb, natural human multi-subtype IFN-alpha, and human IFN-beta.
6. (original) The method of claim 5, wherein the interferon is interferon alpha.
7. (original) The method of claim 5, wherein the interferon is interferon gamma.

U.S. Application No. 10/618,531
Response and RCE filed September 7, 2010
Reply to Final Office Action mailed August 4, 2009

8. (original) The method of claim 5, wherein the interferon is interferon beta.